News and Press Releases

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in

Monday, January 30, 2023

LAST NEWS

Christiane von der Eltz becomes new member of the Executive Board of BERLIN-CHEMIE responsible for the Pharma Germany Division

5/3/2022

Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

11/4/2021

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

10/20/2021

Menarini Pills of Art Junior project launched: Video clips made by the younger generations for children and teenagers

4/9/2021

CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

11/13/2020

Menarini Group: committed to fighting today's COVID-19 pandemic with an eye to averting similar health crises in the future

10/27/2020

Previous 1 2 3 4 Next Last

News archive

Responsibility >>

International >>

Berlin Chemie